Clinical trial
Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients…
NCT00051090 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Withdrawn
Key facts
| NCT number | NCT00051090 |
|---|---|
| Title | Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV |
| Official title | Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Withdrawn |
| Study type | Interventional |
| Conditions | HIV Infections, Hepatitis B |
| Intervention type | Drug |
| Interventions | Telbivudine, Lamivudine, Efavirenz, Didanosine, Abacavir |
| Enrollment | 0 |
| First posted | Jan 6, 2003 |
| Last update posted | Nov 1, 2021 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: